FOLH1 and posterior cortical atrophy: Only one PSMA ligand has been approved by the Food and Drug Administration (FDA), the radiolabeled anti-PSMA antibody capromab pendetide (ProstaScint), which has a low accuracy for PCa detection, as it is a large antibody that binds to the intracellular domain of PSMA 9.